Turbine Aviation Inc (TURA)

[investorx2]

Doc, is this the company you speak of???? HTDS


it is on Investors Hub as well.
5 Billion shares authorized, 1 1/4 Billion shares OS
877 thousand shares in the float, 11 employees
1100 shareholders

-----------------------------------------------


Created: 12/18/2003 3:16:21 PM Board type: Free


HTDS — Hard to Treat Diseases, Inc. - Business Description



The company operates 2 medical subsidiaries in Serbia, Europe and Mainland China

HTDS is a parent co with operations in a East European medical company (Serbia) Slavica Bio Chem Co (formerly ReNuYu Biochmem PLC and ReNuYu Biochem Inc) see: (www.slavicabiochem.com) and in China Mellow Hope.

In Serbia the company's primary focus involves the enhancement and modification of existing approved drugs such as "Virazole" for the purpose of chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatitis C and HIV. Other interests include an on line cosmetics company.

Mellow Hope is China based and the biggest exporter of Biological Vaccines in China. It has a product line that encompasses vaccines for influenza, tetanus, diphtheria and other diseases; Blood based products including human rabies immunoglobulin; and active pharmaceutical ingredient (or APIs) for injection such as celestat in.


Hard To Treat Diseases (HTDS) Corporate Update

TORONTO, Dec 29, 2008 /PRNewswire-FirstCall via COMTEX/ -- Hard to Treat Diseases (HTDS) www.htdsmedical.com (site under construction) is pleased to announce that it has appointed a new interim management. In addition the company has identified a suitable merger operating candidate. The merger candidate is a China based bio chemical company.

As well, the company in the unlikely event of a non completion with the China based medical company is also continuing its negotiations with an East European medical company whose primary focus involves the enhancement and modification of existing approved drugs such as "Virazole" for the purpose of chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis), SARS, Hepatitis C and HIV.

Mr. Keith Roberts the company's interim CEO said "We are looking in all directions for the best opportunities. Our stock is at the lowest price possible and we are resisting all suggestions of any stock splits. We believe that as a Pink Sheet company we can provide the lift to HTDS that will give our shareholders the best return. The China company seems to be the most appealing and possibly may offer the biggest growth however we are not discounting the opportunity with the Europe medical company. It may very well be that we end up with both operating companies. We expect to be able to close either one or both of these deals in the first quarter of 2009".

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

CONTACT: [e-mail]

Hard To Treat Diseases (HTDS) Operational Update

TORONTO, Dec 30, 2008 /PRNewswire-FirstCall via COMTEX/ -- Hard to Treat Diseases (HTDS) www.htdsmedical.com (temporary site up awaiting new website construction) is pleased to announce that it has registered with Pink Sheets for its back office services. The company will begin updating all the information including updating last 2 years financial statements. The company believes that this should improve its ranking to a "Yield" rank from the current "STOP" no information once all the information is submitted and approved by Pink Sheets within the next few days.

The interim management will launched a temporary web site on www.htdsmedical.com. This is a generic web site that is currently being updated.

The company management or its agents plan on visiting the East European and China based medical companies to close the planned merger in January 2009.

Mr. Keith Roberts the company's interim CEO said "In addition to these 2 primary operating companies we also plan on acquiring several small cosmetics type companies as well. This is something that has been in the works for a while."

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

CONTACT: [e-mail]

SOURCE Hard to Treat Diseases

Company Officers
Keith Roberts, Interim CEO, CFO
Ivana Crnomarkovic, COO, Europe, COO, Manuf. Ops.
Cathy Zhao, Chief Admin. Officer
Andrea Zecevic-Rubio, Chief Project Scientist, Director, R&D

Number of Employees
11 as of Dec 30, 2008
-------------------------------------------

Estimated Market Cap
$376,336 as of Dec 31, 2008
Outstanding Shares
1,254,453,000 as of Dec 30, 2008
Authorized Shares
5,000,000,000 as of Dec 30, 2008
Number of Share Holders of Record
1,155 as of Dec 30, 2008
Float
877,644,354 as of Dec 30, 2008
-------------------------------------------

Contact Information

Hard to Treat Diseases, Inc.
2007 Shenzhen Mellow Hope Pharm
Room E-F, 12/F, Jinrun Mansion
No.6019 Shennan Blvd
Shenzen 518040
China

http://www.mellowhope.com

Phone: [phone]